Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Bharat Immunologicals and Biologicals Corporation Ltd (BIBC)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
30.30 -0.46    -1.50%
05:59:22 - Closed. Currency in INR ( Disclaimer )
Type:  Equity
Market:  India
ISIN:  INE994B01014 
S/N:  BIBCL
  • Volume: 63,017
  • Bid/Ask: 30.36 / 30.63
  • Day's Range: 30.00 - 31.44
Bharat Immunologicals Bio 30.30 -0.46 -1.50%

BO:BIBC Financials

 
A brief overview of the BO:BIBC financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Bharat Immunologicals and Biologicals Corporation Ltd over time.

Bharat Immunologicals & Biologicals Corporation Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported revenue was INR 1.64 million compared to INR 267.99 million a year ago. Net loss was INR 49.18 million compared to INR 30.83 million a year ago. Basic loss per share from continuing operations was INR 1.14. Diluted loss per share from continuing operations was INR 1.14.For the six months, revenue was INR 2.65 million. Net loss was INR 95.06 million.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

BIBC Income Statement

Gross margin TTM 11.43%
Operating margin TTM -262.08%
Net Profit margin TTM -241.59%
Return on Investment TTM -9.46%
 Total Revenue  Net Income
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Revenue 76.5
Gross Profit 0.026 -4.52 13.24
Operating Income -47.23 -43.48 -62.16 -47.63
Net Income -49.18 -45.87 -42.93 -46.84

BIBC Balance Sheet

Quick Ratio MRQ 0.19
Current Ratio MRQ 0.33
LT Debt to Equity MRQ 4.45%
Total Debt to Equity MRQ 94.48%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Assets 1881.31 1856.61
Total Liabilities 1094.23 978.65
Total Equity 787.09 877.96 972.73

BIBC Cash Flow Statement

Cash Flow/Share TTM 0
Revenue/Share TTM 1.77
Operating Cash Flow  0.00%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change in Cash
* In Millions of INR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

BIBC Comments

Write your thoughts about Bharat Immunologicals and Biologicals Corporation Ltd
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
kapil arora
kapil arora Apr 07, 2021 12:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
1200 shares @78 what to do ?falling continuously
Reply
0 0
Report
ashwini singh
ashwini singh Apr 07, 2021 12:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hi, just to confirm you still have bibcl pr sold, iam stuck @62, what to do ??
Reply
0 0
Report
Vishal sigar
Vishal sigar Apr 07, 2021 12:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hold
Reply
0 0
Report
Vishal sigar
Vishal sigar Apr 07, 2021 12:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hold
Reply
0 0
Report
Vishal sigar
Vishal sigar Apr 07, 2021 12:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Hold
Reply
0 0
Report
Ankur
Ankur Apr 07, 2021 12:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hold it
Reply
0 0
Report
kapil arora
kapil arora Apr 07, 2021 12:26AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
1200 shares @78 what to do falling continuously
Reply
0 0
Report
Mahendra Oswal
Mahendra Oswal Mar 23, 2021 8:17AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
why falling?? can add more??
Reply
0 0
Report
samir doshi
samir doshi Feb 10, 2021 9:34PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
results?
Reply
0 0
Report
RameshGowd Velagana
RameshGowd Velagana Feb 09, 2021 11:33PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buy BIBCL shares.don't sell
Reply
0 0
Report
Mahendra Oswal
Mahendra Oswal Feb 09, 2021 11:33PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
any insider news??
Reply
0 0
Report
RameshGowd Velagana
RameshGowd Velagana Feb 09, 2021 11:33PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buy BIBCL shares.. don't sell
Reply
0 0
Report
Lanchenba Ningombam
Lanchenba Ningombam Dec 10, 2020 3:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hey buddies. this is not the bharat biotech you're looking for. bharat biotech is govt funded.
Reply
0 0
Report
michailsantosh Mirpuri
michailsantosh Mirpuri Dec 10, 2020 3:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This is the one
Reply
0 0
Report
Lanchenba Ningombam
Lanchenba Ningombam Dec 10, 2020 3:34AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
hey buddies. this is not the bharat biotech you're looking for. bharat biotech is govt funded.
Reply
0 0
Report
STRATEGIC HR Services
STRATEGIC HR Services Jul 05, 2020 9:12AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
buy this share in intraday book the profit with resistant at 20.
Reply
0 0
Report
Tapan Saini
Tapan Saini Jun 30, 2020 4:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
people are really foolish, they are thinking this is the company who invent covid 19 vaccine
Reply
5 1
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email